Stručni rad
TREATMENT OF MULTIPLE SCLEROSIS WITH OCRELIZUMAB – A RETROSPECTIVE 1.5-YEAR ANALYSIS AT DEPARTMENT OF NEUROLOGY, SESTRE MILOSRDNICE UNIVERSITY HOSPITAL CENTRE IN ZAGREB
NEVENA GRBIĆ
orcid.org/0000-0003-1537-3734
; Klinički bolnički centar Sestre milosrdnice, Klinika za neurologiju, Referentni centar Ministarstva zdravstva za neuroimunologiju i neurogenetiku, Zagreb, Hrvatska
MILJENKA-JELENA JURAŠIĆ
; Klinički bolnički centar Sestre milosrdnice, Klinika za neurologiju, Referentni centar Ministarstva zdravstva za neuroimunologiju i neurogenetiku, Zagreb, Hrvatska
LUCIJA ZADRO MATOVINA
; Klinički bolnički centar Sestre milosrdnice, Klinika za neurologiju, Referentni centar Ministarstva zdravstva za neuroimunologiju i neurogenetiku, Zagreb, Hrvatska
IRIS ZAVORERO
orcid.org/0000-0001-9358-1665
; Klinički bolnički centar Sestre milosrdnice, Klinika za neurologiju, Referentni centar Ministarstva zdravstva za neuroimunologiju i neurogenetiku, Zagreb;Kineziološki fakultet Sveučilišta u Zagrebu, Zagreb, Hrvatska
IVANA VINSKI
; Klinički bolnički centar Sestre milosrdnice, Klinika za neurologiju, Referentni centar Ministarstva zdravstva za neuroimunologiju i neurogenetiku, Zagreb, Hrvatska
VANJA BAŠIĆ KES
; Klinički bolnički centar Sestre milosrdnice, Klinika za neurologiju, Referentni centar Ministarstva zdravstva za neuroimunologiju i neurogenetiku, Zagreb; Stomatološki fakultet Sveučilišta u Zagrebu, Zagreb; Medicinski fakultet, Sveučilište Josipa Jurja Strossmayera u Osijeku, Osijek, Hrvatska
Sažetak
Considering importance of T lymphocytes in the pathogenesis of multiple sclerosis, the importance of B lymphocytes in the pathogenesis of the disease is increasingly revealed. Ocrelizumab (Ocrevus®, Roche, Germany) is a monoclonal antibody that targets B cells expressing CD20 antigen. Numerous studies have demonstrated the effi cacy of ocrelizumab in the treatment of relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS). Previous clinical trials have shown that ocrelizumab administration suppresses relapses, disease progression and subclinical disease activity as determined by the method of magnetic resonance imaging. We retrospectively analyzed patients at the Department of Neurology, Sestre milosrdnice University Hospital Centre. Ocrelizumab was administered to 36 patients with RRMS and 13 patients with PPMS. The aim was to present the population of patients administered the drug, their side effects and clinical outcome after administration of the drug, comparing the above data with current knowledge on the drug. In our RRMS group analysis, 47% of patients were administered second treatment cycle and 8% were administered third cycle; 94% of these patients showed no clinical progression of the disease. In the groups of RRMS and PPMS patients, adverse events were recorded in 11% and 23% of patients, respectively. The most common side effects were response to infusion and decrease in lymphocyte count (still at the border of the lower reference value). The analysis of our patients confi rmed previous fi ndings of clinical studies. The drug has been proven to be safe to administer with a low incidence of side effects. Nevertheless, more patients are needed for further and detailed analysis, motivating us for further monitoring and publication of a new analysis in the future.
Ključne riječi
multiple sclerosis; ocrelizumab; treatment; experience
Hrčak ID:
245742
URI
Datum izdavanja:
6.11.2020.
Posjeta: 4.379 *